Latest / The Series A Show with Fexingo: Early-Stage Funding, Pitch Decks, and Startup Milestones / How Venture Debt Became a Startup Lifeline
Transcript
- Lucas: So it's late May 2026, and the IPO window is still pretty much shut for most startups. The S&P 500 is hovering near highs, but the high-growth names that usually go public are getting hammered — NVIDIA's down more than three percent on the week, Alphabet's off three and a half. Luna: Yeah, and that's spilling directly into private market sentiment. Founders who were planning 2025 IPOs have pushed them to 2027, if not later. Lucas: Exactly. And when you can't go public, you can't easily raise a traditional growth equity round at a good price. So more and more startups are turning to a tool that used to be a footnote: venture debt. Luna: Venture debt — basically loans to startups that don't have positive cash flow or hard collateral. Lenders take a lien on IP and sometimes warrants. It's been around for decades, but it feels like suddenly everyone's talking about it. Lucas: Right. And the numbers back that up. According to PitchBook, global venture debt volume hit about $30 billion in 2025, up from maybe $15 billion five years ago. That's a compound annual growth rate of roughly fifteen percent. Luna: But why now? I mean, interest rates are still elevated — the Fed's held at around four and a half percent. That makes debt more expensive than it was in 2021. Lucas: That's the counterintuitive part. Debt is more expensive, but equity is even more expensive in terms of dilution. If you raised a Series B in 2021 at a fifty-times multiple and now you'd be lucky to get twenty times, selling more equity means giving away a huge chunk of the company. Debt lets you extend your runway by twelve to eighteen months without that dilution. Luna: And the lenders have gotten smarter too. The old model was basically Silicon Valley Bank writing simple loans against cash flow. After the SVB collapse in 2023, a whole new crop of lenders emerged — Brex, Mercury, a bunch of specialty funds. Lucas: Yeah, Brex in particular has leaned hard into venture debt. They launched a dedicated lending arm in 2024 and have reportedly deployed over two billion dollars since. Their pitch is speed: you can get a term sheet in days, not weeks, and the docs are standardized. Luna: Which is huge for startups that need to move fast — say, to grab inventory before a tariff change or hire a key engineer before they accept another offer. Equity rounds take three to six months. Debt can close in two weeks. Lucas: But it's not free money. Venture debt typically carries an interest rate of SOFR plus six to nine percent, so call it ten to thirteen percent all-in. Plus warrants — usually around five to ten percent of the loan amount in equity upside. Luna: And if the startup fails, the debt is still owed. It's not convertible — you can't just hand over shares and walk away. The lender can force a liquidation or even push the company into bankruptcy. Lucas: That's the key distinction. SAFE notes and convertible notes are equity-like. Venture debt is real debt. So it's only appropriate for startups with predictable revenue, high gross margins, and a clear path to profitability — or at least a clear path to the next equity round. Luna: Which brings us to the kind of startups using it most. I've been seeing a lot of fintech and SaaS companies go this route. They have recurring revenue, low churn, and they can model their cash flows pretty accurately. Lucas: And the lenders love that. A SaaS company with eighty percent gross margins and negative working capital is a much better credit risk than a hardware startup that needs to buy inventory six months before it sees a dollar of revenue. Luna: Right. And that's actually mirrored in public markets right now. Look at ARKK — Cathie Wood's flagship ETF — it's up two and a half percent this week. But ARKG, the genomics fund, is up nine percent. That tells me investors are rotating into longer-horizon, capital-intensive biotech. Those companies are classic venture debt candidates. Lucas: Great point. Biotech startups burn cash on R&D for years with no revenue. They often use venture debt to finance lab equipment or clinical trials without diluting existing shareholders before a catalyst like FDA approval. Luna: So what should a founder think about before signing a venture debt deal? I mean, beyond the obvious — can we actually make the payments? Lucas: First, understand the covenants. Some lenders require a minimum cash balance or a revenue growth floor. If you trip a covenant, the loan can be called immediately. Second, watch the warrants. A ten percent warrant on a two million dollar loan means the lender gets two hundred thousand dollars' worth of equity at the next round's price. That's not huge, but it adds up. Luna: And third, make sure the maturity aligns with your next raise. If the loan comes due in eighteen months and you can't raise an equity round, you're in trouble. You want at least a six-month cushion. Lucas: Exactly. But when used right, venture debt can be a powerful lever. Take a company doing five million in ARR growing fifty percent year-over-year. If they take a three million dollar venture debt facility at twelve percent interest, they can hire aggressively for two years. If they hit ten million ARR, the equity they would have sold in a Series A would have been far more expensive than that interest. Luna: And you're seeing that math play out more and more. The days of 'growth at all costs' are over. Capital efficiency is the new mantra, and venture debt is a big part of that. Lucas: It's also worth noting that the lenders themselves are evolving. We're seeing non-bank lenders like Hercules Capital and TriplePoint — they're publicly traded, so you can actually buy their stock as a play on venture debt. Hercules yields around nine percent right now. Luna: Interesting. So venture debt isn't just a tool for founders — it's an asset class for investors. And given the IPO drought, it's likely to keep growing. Lucas: One thing I want to flag: not all venture debt is created equal. There's a big difference between a facility from a bank like SVB and one from a fintech like Brex. Bank debt is cheaper but slower, and the relationship is more important. Fintech debt is faster but more expensive and less flexible on covenants. Luna: And there's a newer category — revenue-based financing. Companies like Pipe and Clearco offer advances against future subscription revenue. No warrants, no fixed maturity. But the cost of capital can be even higher. Lucas: Right. So founders need to model out the true cost. A twelve percent interest rate with warrants might be cheaper than a revenue share that takes twenty percent of monthly revenue until you've paid back one point five times the advance. Luna: This is exactly the kind of conversation we love digging into on this show — practical, numbers-driven, and directly useful for people building companies. Lucas: And speaking of that — we keep these episodes ad-free because we think that makes them more useful. If you find value in that, and you want to support the show staying independent and sponsor-free, the link is buy me a coffee dot com slash fexingo. Luna: Yeah, it's a simple way to help us keep doing what we do. No pressure, just if it's something you believe in. Lucas: Alright — back to venture debt. One more angle I want to hit: the role of venture debt in down rounds. If a startup's valuation drops between rounds, existing investors get diluted. But debt doesn't have a valuation — so it's a way to raise capital without marking down the company. Luna: That's a huge psychological win too. Founders hate admitting their company is worth less. Venture debt lets them kick the can without the emotional gut punch of a down round. Lucas: But kicking the can has risks. If the company doesn't improve its fundamentals, the debt just adds leverage to a failing business. We've seen that play out badly — remember the collapse of WeWork? They had billions in debt that accelerated their demise. Luna: True. So venture debt is a tool, not a cure. It amplifies good businesses and destroys bad ones faster. Lucas: Exactly. And the best founders use it strategically — to bridge to a specific milestone, not to delay the inevitable. Luna: We're also seeing more venture debt used in M&A. A startup that wants to acquire a smaller competitor can use debt to finance the deal without diluting existing shareholders. Lucas: That's a great point. And it ties into the broader trend of private companies staying private longer. With fewer exits, companies need creative ways to grow. Venture debt is one piece of that puzzle. Luna: So what's the one takeaway you'd want a founder listening to remember? Lucas: Run the numbers. Model out your dilution under an equity round versus the interest and warrants under debt. If your gross margins are above seventy percent and you have predictable revenue, debt is probably cheaper. If you're pre-revenue or hardware-heavy, stick with equity. Luna: And don't forget to read the fine print on covenants. A seemingly small revenue covenant can become a noose if growth slows. Lucas: Alright, that's our take on venture debt in May 2026. Next episode, I think we should look at how startups are using AI to automate their own fundraising processes — we're seeing some wild experiments there. Luna: I've seen a few tools that draft pitch decks based on your data room. It's creepy but efficient. Let's do it. Lucas: Perfect. Until then, keep building.